Altered IgA-associated gut microbiota and serum IgA are associated with disease severity in alcohol-associated liver disease
Background Alcohol-associated liver disease (ALD) is characterised by dysbiosis, impaired gut barrier function and microbial translocation driving hepatic inflammation. IgA, the dominant mucosal antibody, maintains intestinal homeostasis by coating bacteria. While serum IgA is elevated in advanced ALD, intestinal IgA responses and IgA-bound microbiota remain incompletely defined. Objective To define faecal and serum IgA responses and characterise IgA-bound bacterial communities across the spectrum of ALD. Design Stool and serum IgA were measured in 107 healthy controls (HCs), 191 individuals with alcohol use disorder (AUD) and 360 individuals with alcohol-associated hepatitis (AH). IgA-bound bacteria were isolated using magnetic-activated cell sorting and analysed by 16S ribosomal RNA sequencing. Results Faecal IgA increased with disease severity (AH > AUD > HC) and was associated with distinct microbial compositions. IgA-bound bacterial diversity was reduced in AH and partially recovered after abstinence. Beta diversity demonstrated separation by disease, with enrichment of pathobionts (eg, Streptococcus, Enterococcus, Escherichia/Shigella) and depletion of beneficial taxa (eg, Lachnospiraceae, Ruminococcaceae). IgA-bound taxa correlated with disease severity, with commensals showing inverse and Campylobacteraceae positive associations with Model for End-stage Liver Disease-sodium (MELD-Na). Serum IgA was elevated in AH, decreased after abstinence and did not correlate with faecal IgA. While faecal IgA was not associated with survival, higher serum IgA independently predicted reduced 6-month survival. Conclusion ALD is characterised by altered mucosal IgA responses and IgA-associated microbial alterations. The lack of correlation between faecal and serum IgA suggests regulation of mucosal and systemic IgA responses. Serum IgA may serve as a prognostic biomarker in ALD.
Authors
- Bernd Schnabl (ORCID: https://orcid.org/0000-0002-6281-825X)
- Peter Stärkel (ORCID: https://orcid.org/0000-0003-2938-4442)
- Maximilian Joseph Brol (ORCID: https://orcid.org/0000-0003-2879-7560)
- Sonja Lang (ORCID: https://orcid.org/0000-0001-5710-6103)
- Takao Miwa (ORCID: https://orcid.org/0000-0002-6373-260X)
- Derrick E. Fouts (ORCID: https://orcid.org/0000-0003-4323-7668)
- David Schöler (ORCID: https://orcid.org/0000-0002-2736-9778)
- Cynthia L. Hsu (ORCID: https://orcid.org/0000-0002-2604-1340)
- Linton Freund (ORCID: https://orcid.org/0000-0002-7688-2420)
- AlcHepNet Investigators
Institutions
- J. Craig Venter Institute (US)
- Cliniques Universitaires Saint-Luc (BE)
- Erasmus MC (NL)
- University of California San Diego (US)
- VA San Diego Healthcare System (US)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Gut
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1136/gutjnl-2026-339201
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Association for the Study of Liver Diseases
- Biomedical Laboratory Research and Development, VA Office of Research and Development
- Moores Cancer Center, UC San Diego Health
- Deutsche Forschungsgemeinschaft
- Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture
- National Institute on Alcohol Abuse and Alcoholism
- Division of Diabetes, Endocrinology, and Metabolic Diseases